KeChow Pharma Announces NMPA Approval of Tunlametinib as the First Targeted Therapy for Patients with NRAS Mutated Advanced Melanoma and Previously Treated with PD-1/PD-L1

KeChow Pharma announced that the China National Medical Products Administration has approved tunlametinib for the treatment of patients with NRAS mutated advanced melanoma who were previously treated with PD-1/PD-L1.